Endostatin prevents abnormal blood vessel growth

Article

A research report published in the December issue of the FASEB Journal, describes a new experimental drug, endostatin, which can significantly reduce or eliminate abnormal blood vessel growth within the eye.

A research report published in the December issue of the FASEB Journal, describes a new experimental drug, endostatin, which can significantly reduce or eliminate abnormal blood vessel growth within the eye, thereby offering a possible treatment for advanced age-related macular degeneration (AMD).

Alexander Marneros and co-workers from the Harvard Medical School, US and Niigata University Postgraduate School of Medicine, Japan tested the effects of endostatin on mice lacking the naturally occurring substance and in normal mice. The mice without endostatin were found to be three times more likely to develop advanced AMD than normal mice.

The researchers concluded that endostatin functions as the body's own natural inhibitor of new blood vessel growth and thus presents a possible therapeutic option for macular degeneration.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.